Related content

ReadMax—a novel reading and scoring approach for EGFR gene copy number to predict therapeutic benefit of erlotinib treatment in EGFR wild‐type non‐small‐cell lung cancer

By  

The Journal Of Pathology: Clinical Research, Vol. 1, Iss. 3, 2015-06 ,pp. : 134-143

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II study of erlotinib for previously treated patients with EGFR wildtype nonsmallcell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System

By                      

Molecular and Clinical Oncology, Vol. 2, Iss. 6, 2014-01 ,pp. : 991-996

Spandidos Publications

Access to resources Recommend Favorite

Over-Expression of Egfr is Closely Correlated to Poor Prognosis in Tunisian Patients with Non-Small Cell Lung Adenocarcinoma

By              

Journal of Immunoassay and Immunochemistry, Vol. 35, Iss. 3, 2014-07 ,pp. : 256-268

Taylor & Francis Ltd

Access to resources Recommend Favorite

Assessment of DDR2, BRAF, EGFR and KRAS mutations as therapeutic targets in non-adenocarcinoma lung cancer patients

By                      

Molecular and Clinical Oncology, Vol. 2, Iss. 5, 2014-01 ,pp. : 714-718

Spandidos Publications

Access to resources Recommend Favorite

The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from nonsmallcell lung cancer

By                  

Molecular and Clinical Oncology, Vol. 2, Iss. 1, 2014-01 ,pp. : 116-120

Spandidos Publications

Access to resources Recommend Favorite